Anti-KRT17 / Keratin 17, clone MSVA-117R

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. Cytokeratin 17 (KRT17) is a type I intermediate filament protein expressed in basal and activated epithelial cells, where it plays a key role in epithelial proliferation, stress response, and tissue remodeling. Cytokeratin 17 Antibody for IHC is widely used to detect KRT17 expression in formalin-fixed, paraffin-embedded tissues, enabling detailed analysis of epithelial activation states, basal cell dynamics, and disease-associated alterations in tissue architecture. Cytokeratin 17 antibody, also known as KRT17 antibody or CK17 antibody, is a well-established marker of basal-like and stress-responsive epithelial cell populations.Unlike constitutively expressed keratins such as Cytokeratin 14, KRT17 expression is tightly regulated and is typically low or absent in many normal, quiescent epithelial tissues. Its expression is rapidly induced in response to epithelial stress, including injury, inflammation, and hyperproliferative conditions. This inducible expression pattern makes KRT17 a sensitive indicator of epithelial activation and distinguishes it as a marker of dynamic cellular states rather than static epithelial structure.This Cytokeratin 17 Antibody for IHC incorporates clone MSVA-117R, a recombinant rabbit monoclonal antibody evaluated using tissue microarray (TMA) analysis across a broad panel of normal and cancer tissues. TMA data demonstrate selective cytoplasmic staining in activated epithelial compartments and specific glandular and ductal structures, with minimal background in most non-epithelial tissues. The large-scale TMA format enables direct comparison of KRT17 expression across diverse tissue types, revealing context-dependent expression patterns associated with epithelial activation and disease.In immunohistochemistry, Cytokeratin 17 antibody staining appears as cytoplasmic HRP-DAB brown signal in epithelial cells exhibiting basal or activated phenotypes, with distribution varying according to tissue type and physiological state. TMA-based cancer analysis demonstrates strong and often diffuse expression in multiple carcinoma types, including adenocarcinomas and epithelial tumors with high proliferative activity, where staining highlights tumor cell populations with activated, stress-associated phenotypes. In contrast, normal tissues typically show restricted or absent staining outside of specialized epithelial compartments, providing clear contrast between quiescent and activated states.The detection of KRT17 is particularly informative in studies of tumor biology, epithelial stress response, and disease progression, as its upregulation is associated with increased cellular proliferation, altered differentiation, and aggressive tumor behavior. Its expression has been linked to tumor growth dynamics and may reflect underlying changes in epithelial signaling pathways and cellular adaptation to stress.Overall, Cytokeratin 17 antibody reagents provide reliable and specific detection of KRT17 in basal and activated epithelial cells, supporting immunohistochemical analysis of epithelial stress responses, tumor-associated expression patterns, and disease-related alterations in tissue organization, with strong validation across tissue microarray datasets.This antibody is part of a broader Cytokeratin 17 antibody collection supporting epithelial activation analysis and tumor-associated expression profiling across multiple research applications.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.